The drug makers’ body in a memorandum sent to the Finance Ministry also requested that all excisable goods used for Research & Development purposes should be exempted from central excise duty, besides allowing exemption for capital goods, raw materials, consumables, and reference standards for R&D purposes.
“Pharma manufacturers are required to keep a few boxes of each batch of medicine manufactured till its expiry as ‘control samples’, as per the provisions of the Drug and Cosmetic Act and Rules. These cannot be sold and hence, should be fully exempted from the central excise duty.
Similarly, medicine samples are provided to doctors as ‘physician’s samples’, which should also be kept out of purview of all duties and taxes,” the IDMA said in the memorandum.
It expects that the weighted deduction of 200 per cent of R&D expenses in an in-house facility will be extended for further period of five years, it said.
The industry body said in the last few Budget presentations, the pharma industry has been ‘overlooked’.
“This year we expect the dynamic and forward thinking new government to create a transparent atmosphere of confidence and trust and provide suitable incentives and concessions to keep our growth momentum going,” it said.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)